Intravenous Immunoglobulin for Guillain-Barré Syndrome: How Effective?

Abstract

Guillain-Barré syndrome is an acute inflammatory demyelinating neuropathy characterized by progressive symmetric polyradiculoneuritis, predominantly manifested by weakness and areflexia. In this article, we report our findings in 25 children treated with intravenous immunoglobulin and compare them with the remaining 30 children who received supportive care only. Only supportive care was given to 30 children who were not able to receive intravenous gammaglobulin because of shortcomings in intravenous gammaglobulin availability owing to a poor import during those years. Twenty-five patients were treated with intravenous gammaglobulin; they received intravenous gammaglobulin 0.4 g/kg/day for 5 consecutive days. Seventeen of the intravenous gammaglobulin group had received intravenous gammaglobulin within 10 days after the first symptoms, and eight of them had received intravenous gammaglobulin after the first 10 days. The average time elapsed for the symptoms to reach the maximum level was 6.9 (range 4—12) days in patients receiving intravenous gammaglobulin in the first 10 days, and it was significantly shorter than the time elapsed for the supportive care group (6.9 versus 8.8 days, respectively) (P < .05). Admission to the hospital after the first symptom, disability grade, time to improve in disability grade, the period of hospitalization, and mortality were not different in the intravenous gammaglobulin and supportive care groups (P > .05). Our suggestion for intravenous gammaglobulin treatment in Guillain-Barré syndrome is that if the patient has risk factors for respiratory insufficiency, then the treatment should be started. We more confidently carry out the follow-up of these patients after the results of this study. In conclusion, although it has been reported that intravenous gammaglobulin facilitates improvement in the disease and the decrease in mortality in children with Guillain-Barré syndrome, it has been mentioned in some studies that the intravenous gammaglobulin treatment was not better than supportive care, as in our study. However, further studies are essential to determine when intravenous gammaglobulin should be given to patients having which clinical and laboratory findings. (J Child Neurol 2006;21:972—974; DOI 10.2310/ 7010.2006.00214).

Get full access to this article

View all access options for this article.

References

Asbury AK , Cornblath DR : Assessment of current diagnostic criteria for Guillain-Barré syndrome . Ann Neurol 1990;Suppl:S21—S24.

Zaferious DI , Kontopoulos EE , Katzos GS , et al: Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome. Brain Dev 1997;19:323—325.

Ropper AH : Severe acute Guillain-Barré syndrome. Neurology 1986; 36:429—432.

Cole GF , Matthew DJ : Prognosis in severe Guillain-Barré syndrome. Arch Dis Child 1987;62:288—291.

Briscoe DM , McMenamin JB , O'Donohoe NV: Prognosis in Guillain-Barré syndrome. Arch Dis Child 1987;62:733—735.

Bradshaw DY , Jones HR Jr: Guillain-Barré syndrome in children: Clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15:500—506.

Lawn ND , Wijdicks EF : Fatal Guillain-Barré syndrome. Neurology 1999 ;52:635—638.

Epstein MA , Sladky JT : The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990;28:65—69.

Vajsar J. , Sloane A. , Wood E. , Murphy EG : Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome. Arch Pediatr Adolesc Med 1994;148:1210—1212.

10.

Wang CH , Trifiletti R. , Gold AP , De Vivo DC : Plasma exchange versus intravenous immunoglobulin as treatment for childhood-onset Guillain-Barré syndrome, abstract. Ann Neurol 1992;32:440.

11.

Kanra G. , Ozon A. , Vajsar J. , et al: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1997;1:7—12.

12.

Eberle E. , Brink J. , Azen S. , White D. : Early predictors of incomplete recovery in children with Guillain-Barré polyneuritis . J Pediatr 1975; 86:356—359.

13.

Vajsar J. , Fehlings D. , Stephens D. : Long-term outcome in children with Guillain-Barré syndrome. J Pediatr 2003;142:305—309.

14.

Jones HR : Childhood Guillain-Barré syndrome: Clinical presentation, diagnosis, and therapy . J Child Neurol 1996;11:4—12.

15.

Hankey GJ : Guillain-Barre syndrome in Western Australia, 1980-1985. Med J Aust 1987;146:130—133.

16.

Lamont PJ , Johnston HM , Berdoukas VA : Plasmapheresis in children with Guillain-Barré syndrome. Neurology 1991;41:1928—1931.

17.

Jansen PW , Perkin RM , Ashwal S. : Guillain-Barré syndrome in childhood: Natural course and efficacy of plasmapheresis . Pediatr Neurol 1993;9:16—20.

18.

Freezer NJ , Robertson CF : Tracheostomy in children with Guillain Barré syndrome. Crit Care Med 1990;18:1236—1238.

19.

Kleyweg RP , van der Meche FG , Loonen MC , et al: The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry 1989;52:853—856.

20.

Ouvrier RA , McLeod JG , Pollard JD : Peripheral neuropathy in childhood, in Procopis PG , Rapin I (eds): The International Review of Child Neurology, New York, Raven Press, 1990, 39—49.

21.

Sakakihara Y. , Kamoshita S. : Age-associated changes in the symptomatology of Guillain-Barré syndrome in children. Dev Med Child Neurol 1991;33:611—616.

22.

Hirano Y. , Osawa M. , Ohya T. , et al: Guillain-Barre syndrome in children: Questionnaire survey on therapies and clinical outcomes. Shonika Rinsyo (Tokyo) 2000;53:77—85.

23.

Graf WD , Katz JS , Eder DN , et al: Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care. Neurology 1999;52:1494—1497.

24.

Ammache Z. , Afifi AK , Brown CK , Kimura J. : Childhood Guillain-Barré syndrome: Clinical and electrophysiologic features predictive of outcome. J Child Neurol 2001 ;16:477—483.

25.

Reisin RC , Pociecha J. , Rodriguez E. , et al: Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14:308—312.

26.

Korinthenberg R. , Monting JS : Natural history and treatment effects in Guillain-Barré syndrome: A multicenter study. Arch Dis Child 1996; 74:281—287.

27.

Yata J. , Nihei K. , Ohya T. , et al: High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Int 2003;45: 543—549.